Article
Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non–small cell lung cancer
2026-03-05
Abstract excerpt
Patients with advanced non–small cell lung cancer (NSCLC) and mutations in epidermal growth factor receptor (EGFR) benefit from EGFR tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation EGFR TKI, is standard first-line therapy for EGFR-mutated NSCLC, but most patients develop resistance to it. Here, we demonstrate that increased formation of primary cilia, microtubule-based sensory organelles, is ass...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 12d479f3-04b8-575d-aeda-98561c3b69ca
- DOI
- 10.64898/2026.03.03.709408
